During the last three months, 9 analysts shared their evaluations of Quest Diagnostics (NYSE:DGX), revealing diverse outlooks from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have set 12-month price targets for Quest Diagnostics, revealing an average target of $179.44, a high estimate of $191.00, and a low estimate of $170.00. This current average has increased by 3.19% from the previous average price target of $173.89.

Diving into Analyst Ratings: An In-Depth Exploration

The analysis of recent analyst actions sheds light on the perception of Quest Diagnostics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Quest Diagnostics's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Quest Diagnostics analyst ratings.

Delving into Quest Diagnostics's Background

Unraveling the Financial Story of Quest Diagnostics

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Net Margin: Quest Diagnostics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.39% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Quest Diagnostics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Quest Diagnostics's ROA excels beyond industry benchmarks, reaching 1.36%. This signifies efficient management of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 1.05, Quest Diagnostics adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.